Navigation Links
Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
Date:11/11/2011

DURHAM, N.C., Nov. 11, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced a late-breaking poster presentation at the American Society of Nephrology's (ASN) Kidney Week 2011 Annual Meeting being held November 8-13, 2011 in Philadelphia, PA.  

V. Ram Peddi, MD, Transplant Nephrologist and Director of Kidney Transplant Research at California Pacific Medical Center, will present data from Chimerix's Phase 1/2 trial evaluating CMX001 in transplant patients with BK virus (BKV) infection.  The poster presentation, entitled "CMX001 Was Well-Tolerated and Without Nephrotoxicity in Renal Transplant and Hematopoietic Stem Cell Transplant Recipients with BK Virus Infection in a Prospective, Randomized, Double-Blind Study," is part of the "Late-Breaking Clinical Trials Poster" session and begins at 10:00 am on Saturday, November 12 at the Philadelphia Convention Center.

"In the Phase 1/2 trial, CMX001 was generally safe and well tolerated when administered to renal transplant (RT) and hematopoietic stem cell transplant (HSCT) recipients," stated Wendy Painter, MD, MPH, Chief Medical Officer of Chimerix, Inc.  "Importantly, no signs of nephrotoxicity were seen following five weekly oral doses of 40 mg and the pharmacokinetics of CMX001 and cidofovir were similar between kidney transplant and bone marrow transplant recipients."  These findings are consistent with results from other CMX001 clinical trials and based on Chimerix's experience with subjects treated under emergency INDs.

CMX001 is being tested in ongoing placebo-controlled clinical trials and in open-label treatment protocols for the prophylaxis, pre-emption and treatment of double-stranded DNA (dsDNA) viruses, including herpesviruses and adenoviruses, and as a potential biodefense countermeasure in the event of a smallpox release.  Data from an ongoing, placebo-controlled Phase 2 clinical trial
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chimerix to Present at Stifel Nicolaus 2011 Healthcare Conference
2. Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients
3. Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract
4. Chimerix to Present at Two Upcoming Investor Conferences
5. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
6. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
7. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
8. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
9. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
10. Chimerix to Present at Upcoming Investor Conferences
11. Chimerix Initiates Phase 1 Study of CMX157
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... July 03, 2015 , ... The Alexander Group, a ... service industries alike-- typically known for its consummate professionalism-- embarks each year in ... and break from their day jobs. , "Our motto has always been work ...
(Date:7/3/2015)... -- Pomerantz LLP announces that a class action lawsuit has ... "Company")(NYSE: PBYI ) and certain of its officers.   ... Central District of California , and ... consisting of all persons or entities who purchased Puma ... inclusive (the "Class Period").  This class action seeks to ...
(Date:7/2/2015)... Md. , July 2, 2015  Spherix Incorporated ... to the fostering and monetization of intellectual property, today ... of Spherix Incorporated v. Verizon Services Corp. et ... District Court for the Eastern District of ... on July 1, 2015 interpreting certain key claims in ...
(Date:7/1/2015)... ... July 01, 2015 , ... It is now possible to separate two common ... emission computed tomography (SPECT) according to researchers from Amen Clinics, UCLA, Thomas Jefferson ... scans and is believed to be the largest brain imaging study ever, will be ...
Breaking Biology Technology:The Alexander Group Declares Their Independence with a Bit of Levity 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4
... Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) today announced that ... on Wednesday, October 29,2008, after the market closes. The ... 5:00 p.m. ET, which will be open to the ... company will review,the financial results and discuss other business ...
... Global Vision, the leader in,automated proofreading solutions ... the top 20 pharmaceutical companies have selected Global,Vision ... and artwork errors from,occurring in their packaging process. ... a reduction of quality issues and,costs, along with ...
... Oct. 22 Micromet, Inc.,(Nasdaq: MITI ), ... treatment of cancer, inflammation and autoimmune,diseases, today announced ... audio,webcast on Thursday, November 6, 2008, at 9:00 ... discuss its third quarter 2008 financial results.,Micromet anticipates ...
Cached Biology Technology:Sangamo BioSciences Announces Third Quarter Conference Call and Webcast 2Sangamo BioSciences Announces Third Quarter Conference Call and Webcast 3Global Vision Recognized for Helping Pharmaceutical Companies Achieve Complete Artwork and Copy Accuracy in their Packaging Process 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results 3Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results 4
(Date:6/24/2015)... SAN JOSE, Calif. , June 24, 2015 ... leading developer of human interface solutions, today announced ... fingerprint sensor to provide secure authentication for its ... Having recently reached more than 200 million shipments ... shipment with Sharp reinforces Synaptics, strength, scalability and ...
(Date:6/23/2015)... 23, 2015   Valencell, a leader ... of a recent study that illustrates its PerformTek ... during activity. In a study conducted at Valencell,s ... with the Apple Watch against a chest strap ... during activity. The study demonstrated that Valencell,s biometric ...
(Date:6/17/2015)... Germany , June 17, 2015 ... today launched new Investigator ® STR assay kits for ... the United States . The new genetic fingerprint kits ... markers (short tandem repeats or STRs) for DNA matching. They ... quality of DNA in each sample, a novel QIAGEN technology ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... areas a serious ecological threat to the maritime ... environment, e.g. the increase of fish-eating animals like ... of the new guiding principles of political decision-making ... approach" should be used instead of traditional protection ...
... of commercial materials, lighter and cheaper is usually better, ... and special properties, such as a material,s ability to ... a physical or magnetic force. ,A new class of ... by two research teams headed by Peter Mllner at ...
... five times as likely as U.S-born children to suffer from ... Health Department study, and the risk is highest among the ... lead poisoning in 2002, published online in the American Journal ... lived abroad within the previous six months were 11 times ...
Cached Biology News:Fisheries should be regarded as a part of the maritime environment 2Metal foam has a good memory 2Study shows immigrant children are at increased risk of lead poisoning 2Study shows immigrant children are at increased risk of lead poisoning 3
... Mouse Antibody to Human Cytokeratin TYPE II ... (Type II) keratins. Including epidermal cell keratin ... 58kD, 65kD and 67kD. Broad keratin reactivity ... and cornea. Immunogen: ...
BD BioCoat Fibronectin 150 mm Culture Dishes...
... number is a new product number, created ... showing no availability yet, please order under ... customer service for assistance. ID ... surface area 500 cm 2 D ...
... for maximum packaging efficiencies of cDNA and genomic ... Using a test insert with Novagen's l vector ... x 10^8 pfu/g ligated l control DNA) are ... to use; simply add up to 5 g ...
Biology Products: